S'abonner

An abnormal cerebroplacental ratio (CPR) is predictive of early childhood delayed neurodevelopment in the setting of fetal growth restriction - 05/09/19

Doi : 10.1016/j.ajog.2019.06.026 
Cathy Monteith, PhD a, , Karen Flood, MD a, Ragamallika Pinnamaneni, MRCPI d, Terri A. Levine, PhD e, Fiona A. Alderdice, BSSc, PhD e, f, Julia Unterscheider, PhD g, Fionnuala M. McAuliffe, MD h, Patrick Dicker, PhD b, Elizabeth C. Tully, PhD a, Fergal D. Malone, MD a, Adrienne Foran, MD c
a Department of Obstetrics & Gynecology, Royal College of Surgeons, Ireland, Dublin Ireland 
b Department of Epidemiology & Public Health, Royal College of Surgeons, Ireland, Dublin Ireland 
c Department of Neonatology, Royal College of Surgeons, Ireland, Dublin Ireland 
d Department of Neonatology, Rosie Maternity Hospital, Cambridge, United Kingdom 
e School of Nursing and Midwifery, Queen’s University Belfast, Belfast, Northern Ireland 
f National Perinatal Epidemiology Unit, University of Oxford, Oxford, United Kingdom 
g Department of Obstetrics & Gynecology, University of Melbourne, Royal Women’s Hospital, Melbourne, Australia 
h Obstetrics & Gynecology, UCD Perinatal Research Centre, University College Dublin, National Maternity Hospital, Dublin, Ireland 

Corresponding author: Cathy Monteith, PhD, RCSI.

Abstract

Background

Fetal growth restriction accounts for a significant proportion of perinatal morbidity and death. The cerebroplacental ratio is gaining much interest as a useful tool in differentiating the “at-risk” fetus in both fetal growth restriction and appropriate-for-gestational-age pregnancies. The Prospective Observational Trial to Optimize Pediatric Health in Fetal Growth Restriction group has demonstrated previously that the presence of this “brain-sparing” effect is associated significantly with adverse perinatal outcomes in the fetal growth restriction cohort. However, data about neurodevelopment in children from pregnancies that are complicated by fetal growth restriction are sparse and conflicting.

Objective

The aim of the Prospective Observational Trial to Optimize Pediatric Health in Fetal Growth Restriction NeuroDevelopmental Assessment Study was to determine whether children born after fetal growth-restricted pregnancies are at additional risk of adverse early childhood developmental outcomes compared with children born small for gestational age. The objective of this secondary analysis was to describe the role of cerebroplacental ratio in the prediction of adverse early childhood neurodevelopmental outcome.

Study Design

Participants were recruited prospectively from the Perinatal Ireland multicenter observational Prospective Observational Trial to Optimize Pediatric Health in Fetal Growth Restriction study cohort. Fetal growth restriction was defined as birthweight <10th percentile with abnormal antenatal umbilical artery Doppler indices. Small for gestational age was defined similarly in the absence of abnormal Doppler indices. Cerebroplacental ratio was calculated with the pulsatility indices of the middle cerebral artery and divided by umbilical artery with an abnormal value <1. Children (n=375) were assessed at 3 years with the use of the Ages and Stages Questionnaire and the Bayley Scales of Infant and Toddler Development, 3rd edition. Small-for-gestational-age pregnancies with normal Doppler indices were compared with (1) fetal growth-restricted cases with abnormal umbilical artery Doppler and normal cerebroplacental ratio or (2) fetal growth restriction cases with both abnormal umbilical artery and cerebroplacental ratio. Statistical analysis was performed with statistical software via 2-sample t-test with Bonferroni adjustment, and a probability value of .00625 was considered significant.

Results

Assessments were performed on 198 small-for-gestational-age children, 136 fetal growth-restricted children with abnormal umbilical artery Doppler images and normal cerebroplacental ratio, and 41 fetal growth-restricted children with both abnormal umbilical artery Doppler and cerebroplacental ratio. At 3 years of age, although there were no differences in head circumference, children who also had an abnormal cerebroplacental ratio had persistently shorter stature (P=.005) and lower weight (P=.18). Children from fetal growth restriction–affected pregnancies demonstrated poorer neurodevelopmental outcome than their small-for-gestational-age counterparts. Fetal growth-restricted pregnancies with an abnormal cerebroplacental ratio had significantly poorer neurologic outcome at 3 years of age across all measured variables.

Conclusion

We have demonstrated that growth-restricted pregnancies with a cerebroplacental ratio <1 have a significantly increased risk of delayed neurodevelopment at 3 years of age when compared with pregnancies with abnormal umbilical artery Doppler evidence alone. This study further substantiates the benefit of routine assessment of cerebroplacental ratio in fetal growth-restricted pregnancies and for counseling parents regarding the long-term outcome of affected infants.

Le texte complet de cet article est disponible en PDF.

Key words : cerebroplacental ratio, Doppler, growth restriction, neurodevelopment, pulsatility index, small for gestational age, umbilical artery


Plan


 Supported by the Health Research Board (HRB) of Ireland and Friends of the Rotunda; all sonographer posts were HRB funded through Perinatal Ireland–IMA/2005/3; a PhD studentship from Queen’s University Belfast in Northern Ireland (T.A.L); and by funding from Temple Street Children’s Hospital, Dublin, Ireland, for the purchase of equipment and additional funding from the Wellcome Trust, UK, for her salary during the PANDA study (R.P.).
 The authors report no conflict of interest.
 Cite this article as: Monteith C, Flood K, Pinnamaneni R, et al. An abnormal cerebroplacental ratio (CPR) is predictive of early childhood delayed neurodevelopment in the setting of fetal growth restriction. Am J Obstet Gynecol 2019;221:273.e1-9.


© 2019  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 221 - N° 3

P. 273.e1-273.e9 - septembre 2019 Retour au numéro
Article précédent Article précédent
  • A comorbidity-based screening tool to predict severe maternal morbidity at the time of delivery
  • Sarah Rae Easter, Brian T. Bateman, Valerie Horton Sweeney, Karen Manganaro, Sarah C. Lassey, Joshua J. Gagne, Julian N. Robinson
| Article suivant Article suivant
  • Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis
  • Leanna S. Sudhof, Scott A. Shainker, Brett D. Einerson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.